A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Inclusion Criteria:

1. Male or female, age ≥18 years at the time of signing informed consent.

2. Body mass index (BMI) ≥28 kg/m^2 at screening, OR BMI ≥24 kg/m^2 at screening withthe presence of at least one of the following weight-related complications:

• Hypertension (defined as repeated, i.e. at least 3 measurements in restingcondition, systolic blood pressure (SBP) values of ≥140 mmHg and/or diastolicblood pressure (DBP) values of ≥90 mmHg in the absence of anti-hypertensivetreatment, or intake of at least 1 anti-hypertensive drug to maintain anormotensive blood pressure)

• Dyslipidaemia (defined as at least 1 lipid-lowering treatment required tomaintain normal blood lipid levels, or low density lipoprotein (LDL)cholesterol ≥160 mg/dL (≥4.1 mmol/L), or triglycerides ≥150 mg/dL (≥1.7mmol/L), or high density lipoprotein (HDL) cholesterol <40 mg/dL (<1.0 mmol/L)for men or HDL cholesterol <50 mg/dL (<1.3 mmol/L) for women)

• Obstructive sleep apnoea

• Cardiovascular disease (CVD) (e.g. heart failure (HF) with New York HeartAssociation (NYHA) functional class II-III, history of ischaemic orhaemorrhagic stroke or cerebrovascular revascularisation procedure [e.g.carotid endarterectomy and/or stent], myocardial infarction (MI), coronaryartery disease, or peripheral vascular disease)

• Type 2 diabetes mellitus (T2DM) diagnosed at least 180 days prior to screening (glycosylated haemoglobin A1c (HbA1c) ≥6.5% (48 mmol/mol) and <10% (86mmol/mol), and fasting plasma glucose (FPG) ≤11.1 mmol/L measured by thecentral laboratory at screening --- Currently treated with either: diet and exercise alone or stable treatment (for at least 3 months prior to screening) with metformin, sodium-glucosecotransporter-2 inhibitor (SGLT2i) inhibitor, acarbose, sulfonylurea, orglitazone as single agent therapy, or up to 3 anti-hyperglycaemia medications (metformin, SGLT2i, acarbose, sulfonylurea, or glitazone) according to locallabel

• Non-alcoholic steatohepatitis (NASH), as assessed in medical records byhistological liver assessment (within the last 6 months)

3. History of at least one self-reported unsuccessful dietary effort to lose bodyweight

4. Signed and dated written informed consent in accordance with International Councilfor Harmonisation of Technical Requirements for Pharmaceuticals for Human Use-GoodClinical Practice (ICH-GCP) and local legislation prior to admission to the trial

5. Woman of childbearing potential (WOCBP) must be ready and able to use highlyeffective methods of birth control per ICH M3 (R2) that result in a low failure rateof less than 1% per year when used consistently and correctly. A list ofcontraception methods meeting these criteria and instructions on the duration oftheir use will be provided in the participant information.

Further inclusion criteria apply.

Exclusion Criteria:

(A) Obesity:

1. Body weight change (self-reported) >5% within 3 months before screening.

2. Treatment with any medication for the indication obesity within 3 months beforescreening.

3. Previous or planned (during the trial period) treatment for obesity with surgery ora weight loss device, or prior surgery of the GI tract that could interfere withbody weight The following are allowed: (1) liposuction and/or abdominoplasty, ifperformed >1 year before screening, (2) lap banding, if the band has been removed >1year before screening, (3) intragastric balloon, if the balloon has been removed >1year before screening, (4) duodenal-jejunal bypass sleeve, if the sleeve has beenremoved >1 year before screening, (5) appendectomy, (6) simple hernia repair, or (7)cholecystectomy

4. Have obesity induced by other endocrinologic disorders (for example, CushingSyndrome) or diagnosed monogenetic or syndromic forms of obesity (for example,melanocortin 4 receptor deficiency, leptin deficiency, or Prader Willi Syndrome) (B)Diabetes-related for participants with T2DM:

5. Treatment with any medication for the indication of T2DM other than stated in theinclusion criteria within 3 months before screening (i.e. insulin, amylin analogues,glucagon-like peptide-1 receptor (GLP- 1R)) agonists, GLP-1Ragonist/insulin/glucose-dependent insulinotropic polypeptide (GIP) combinations, anddipeptidyl peptidase 4 inhibitor (DPP-4i))

6. New initiation of any other glucose-lowering investigational drug within 3 monthsprior to screening for this trial

7. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy, verifiedby an eye examination within 3 months prior to screening or in the period betweenscreening and randomisation Further exclusion criteria apply.